After<unk>  is administered (100 mg by mouth once daily), the average steady state and Cmax and AUC for patients with cardiovascular failure is 350 mcg/L and 6,680 mcg/h/L with a Tmax of one hour.<unk>  has a positive food effect, and therefore patients are advised to consume food with the drug for an oral bioavailability of 93%.<unk>  is extensively protein-bound in plasma .<unk>  is primarily metabolized via phase II conjugation reactions, with a minor CYP-mediated oxidative metabolite. The major metabolite is glucuronidated and inactive. The typical half-life profile for patients with heart failure is 30 hours.<unk>  has a decreased clearance and was observed to have a 1.6 g/L clearance in patients with systolic heart failure.
Vericiguat
Riociguat
Bosentan
Ambrisentan
Sitaxentan
Colestilan
Darusentan
Macitentan